Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 9, 2015, Pages 1315-1320

  Avemaria, Francesca ^a,b   Carrera, Paola ^b   Lapolla, Annunziata ^c   Sartore, Giovanni ^c   Chilelli, Nino Cristiano ^c   Paleari, Renata ^a   Ambrosi, Alessandro ^d   Ferrari, Maurizio ^b,d   Mosca, Andrea ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

deglycation; diabetes; fructosamine 3 kinase (FN3K); glycated hemoglobin (HbA1c); glycation; single nucleotide polymorphisms

Indexed keywords

ENZYME; FRUCTOSAMINE 3 KINASE; UNCLASSIFIED DRUG; FRUCTOSAMINE-3-KINASE; PHOSPHOTRANSFERASE;

ARTICLE; CAUCASIAN; COHORT ANALYSIS; DIABETIC PATIENT; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GLYCATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; DIABETES MELLITUS; ENZYMOLOGY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPING TECHNIQUE; GLYCOSYLATION; METABOLISM;

COHORT STUDIES; DIABETES MELLITUS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPING TECHNIQUES; GLYCOSYLATION; HUMANS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 84938487320     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0207     Document Type: Article

References (41)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 27 million participants. Lancet 2011;378:31-40.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.
3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
4. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. J Am Med Assoc 2002;288:2579-88.
5. Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Exp Opinion Invest Drugs 2002;11:1205-23.
6. Morgan PE, Dean RT, Davies MJ. Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch Biochem Biophys 2002;403:259-69.
7. Ames JM. The Maillard reaction. In: Hudson BJ, editor. Progress in food proteins-biochemistry. London: Elsevier Applied Science, 1992:99-153.
8. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001;56:1-21.
9. Chilelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view. Nutr Metab Cardiovasc Dis 2013;23:913-9.
10. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al.; National Academy of Clinical Biochemistry. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011;34:1419-23.
11. American Diabetes Association. Glycemic targets. Sec. 6. In: Standards of medical care in diabetes 2015. Diabetes Care 2015;38:S33-40.
12. The International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
13. Wiame E, Delpierre G, Collard F, Van Schaftingen E. Identification of a pathway for the utilization of the Amadori product fructoselysine in Escherichia coli. J Biol Chem 2002;277:42523-9.
14. Monnier VM, Wu X. Enzymatic deglycation with amadoriase enzymes from Aspergillus sp. as a potential strategy against the complications of diabetes and aging. Biochem Soc Trans 2003;31:1349-53.
15. Delpierre G, Rider MH, Collard F, Stroobant V, Vanstapel F, Santos H, et al. Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase. Diabetes 2000;49:1627-34.
16. Petersen A, Szwergold BS, Kappler F, Weingarten M, Brown TR. Identification of sorbitol 3-phosphate and fructose 3-phosphate in normal and diabetic human erythrocytes. J Biol Chem 1990;265:17424-7.
17. Petersen A, Kappler F, Szwergold BS, Brown TR. Fructose metabolism in the human erythrocyte. Phosphorylation to fructose 3-phosphate. Biochem J 1992;284:363-6.
18. Szwergold BS, Howell S, Beisswenger PJ. Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 2001;50:2139-47.
19. Collard F, Delpierre G, Stroobant V, Matthijs G, Van Schaftingen E. A mammalian protein homologous to fructosamine-3-kinase is a ketosamine-3-kinase acting on psicosamines and ribulosamines but not on fructosamines. Diabetes 2003;52:2888-95.
20. Delplanque J, Delpierre G, Opperdoes FR, Van Schaftingen E. Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein. J Biol Chem 2004:279:46606-13.
21. Conner JR, Beisswenger PJ, Szwergold BS. The expression of the genes for fructosamine-3-kinase and fructosamine-3-kinaserelated protein appears to be constitutive and unaffected by environmental signals. Biochem Biophys Res Commun 2004;323:932-6.
22. Delpierre G, Collard F, Fortpied J, Van Schaftingen E. Fructosamine 3-kinase is involved in an intracellular glycation pathway in human erythrocytes. Biochem J 2002;365:801-8.
23. Veiga-da-Cunha M, Jacquemin P, Delpierre G, Godfraind C, Théate I, Vertommen D, et al. Increased protein glycation in fructsamine 3-kinase-deficient mice. Biochem J 2006;399: 257-64.
24. Pascal SM, Veiga-da-Cunha M, Gilon P, Van Schaftingen E, Jonas JC. Effects of fructosamine-3-kinase deficiency on function and survival of mouse pancreatic islets after prolonged culture in high glucose or ribose concentrations. Am J Physiol Endocrinol Metab 2010;298:E586-96.
25. Delpierre G, Vertommen D, Communi D, Rider MH, Van Schaftingen E. Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin. J Biol Chem 2004;279:27613-20.
26. Van Schaftingen E, Collard F, Wiame E, Veiga-da-Cunha M. Enzymatic repair of Amadori products. Amino Acids 2012;42:1143-50.
27. Delpierre G, Veiga-da-Cunha M, Vertommen D, Buysschaert M, Van Schaftingen E. Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin glycation at specific sites. Diabetes Metab 2006;32:31-9.
28. Mohás M, Kisfali P, Baricza E, Mérei A, Maász A, Cseh J, et al. A polymorphism within the Fructosamine-3-kinase gene is associated with HbA1c levels and the onset of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2010;118:209-12.
29. Tanhäuserová V, Kuricová K, Pácal L, Bartáková V, Rehoová J, Svojanovský J, et al. Genetic variability in enzymes of methabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality. Clin Chem Lab Med 2014;52:77-83.
30. Skrha JJr, Muravská A, Fleka M, Horová E, Novák J, Novotný A, et al. Fructosamine 3-kinase and glyoxalase I polymorphisms and their association with soluble RAGE and adhesion molecules in diabetes. Phisiol Res 2014;63:S283-91.
31. Mosca L, Penco S, Patrosso MC, Marocchi A, Lapolla A, Sartore G, et al. Genetic variability of the fructosamine 3-kinase gene in diabetic patients. Clin Chem Lab Med 2011;49:803-8.
32. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010;362:166-76.
33. Soranzo N, Senna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common genetic variants at 10 genomic loci influence hemoglobin A1c levels via glycemic and nonglycemic pathways. Diabetes 2010;59:3229-39.
34. Chen P, Takeuchi F, Lee JY, Li H, Wu JY, Liang J. Multiple nonglycemic genomic loci are newly associated with blood level of glycated hemoglobin in East Asians. Diabetes 2014;63:2551-62.
35. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015;518:317-30.
36. Groop L, Flemming P. Genetics of diabetes-Are we missing the genes or the disease? Mol Cell Endocrinol 2014;382:726-39.
37. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Available from: http://www.staff.ncl.ac.uk/philip. home/who-dmc.htm. Accessed: 22 April 2015.
38. Bry L, Chen PC, Sacks DB. Effects of haemoglobin variants and chemically modified derivatives on assays for glycohaemoglobin. Clin Chem 2001;47:153-63.
39. Rabbani N, Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011;22:309-17.
40. Leslie RD, Cohen RM. Biologic variability in plasma glucose, hemoglobin A1c and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol 2009;3:635-43.
41. Cohen RM, Smith EP. Frequency of HbA1c discordance in estimating blood glucose control. Curr Opin Clin Nutr Metab Care 2008;11:512-7.